MCID: HYP006
MIFTS: 48

Hypertensive Heart Disease

Categories: Cardiovascular diseases

Aliases & Classifications for Hypertensive Heart Disease

MalaCards integrated aliases for Hypertensive Heart Disease:

Name: Hypertensive Heart Disease 12 52 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:11516
ICD10 33 I11 I11.9 I11.0
ICD9CM 35 402 402.9
UMLS 69 C0152105

Summaries for Hypertensive Heart Disease

Disease Ontology : 12 A heart disease that is caused by high blood pressure.

MalaCards based summary : Hypertensive Heart Disease is related to myocardial infarction and heart disease. An important gene associated with Hypertensive Heart Disease is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Pathways in cancer and Colorectal Cancer Metastasis. The drugs Irbesartan and Ramipril have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and endothelial, and related phenotypes are cardiovascular system and growth/size/body region

Wikipedia : 72 Hypertensive heart disease includes a number of complications of high blood pressure that affect the... more...

Related Diseases for Hypertensive Heart Disease

Diseases related to Hypertensive Heart Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 139)
id Related Disease Score Top Affiliating Genes
1 myocardial infarction 25.1 ACE AGT AGTR1 CTF1 MMP1 MMP2
2 heart disease 10.8
3 synovial chondromatosis 10.6 ACE NPPB
4 clitoris cancer 10.6 ACE AGTR1
5 pleomorphic liposarcoma 10.5 ACE NPPB
6 keratopathy 10.5 CD36 MMP1
7 islet cell tumor 10.5 ACE NPPB
8 pelizaeus-merzbacher-like disease 10.5 ACE AGT
9 hypodontia of incisors and premolars 10.4 ACE CYP11B2
10 suppurative otitis media 10.4 ACE NPPB
11 broad ligament malignant neoplasm 10.4 ACE AGTR1 NPPB
12 familial isolated pituitary adenoma 10.4 AGT AGTR1
13 idiopathic juxtafoveal retinal telangiectasia 10.3 ACE NPPB NR3C2
14 placental abruption 10.3 ACE NPPB NR3C2
15 hereditary cerebral amyloid angiopathy 10.3 AGTR1 CYP11B2
16 mental retardation cataracts calcified pinnae myopathy 10.3 AGT AGTR1
17 liver lymphoma 10.3 MMP1 MMP2
18 cardiomyopathy 10.3
19 gait apraxia 10.2 MMP1 MMP2
20 hypertrichosis of eyelid 10.2 ACE AGTR1 NR3C2
21 perrault syndrome 10.2 AGTR1 CD36 NR3C2
22 congenital methemoglobinemia 10.2 CD36 MMP2
23 craniosynostosis 7 10.2 ACE AGT NPPB
24 lymphadenitis 10.2 ACE AGTR1
25 cataract, autosomal dominant congenital 4 10.1 ACE AGT AGTR1
26 potato nose 10.1 ACE AGT AGTR1
27 chylocele of tunica vaginalis 10.1 ACE AGT AGTR1
28 retinitis pigmentosa 17 10.1 ACE AGT AGTR1
29 fibular aplasia ectrodactyly 10.1 ACE AGT AGTR1
30 cascade stomach 10.1 ACE AGT AGTR1
31 renal tubular dysgenesis 10.1 ACE AGT AGTR1
32 joint disorders 10.1 ACE AGT AGTR1
33 hemoglobin lepore-beta-thalassemia syndrome 10.1 MMP1 MMP9
34 congenital bilateral megacalycosis 10.1 ACE AGT AGTR1
35 episodic ataxia 10.1 ACE AGT AGTR1
36 exocrine pancreatic insufficiency 10.1 ACE AGT AGTR1
37 microphthalmia, isolated, with coloboma 7 10.1 ACE CYP11B2 NR3C2
38 early myoclonic encephalopathy 10.1 MMP1 MMP9
39 trabecular follicular adenocarcinoma 10.1 CYP11B2 NR3C2
40 ectropion 10.1 MMP1 MMP9
41 chronic myelomonocytic leukemia 10.1 ACE AGT AGTR1
42 salt and pepper syndrome 10.1 CD36 MMP1 MMP2
43 bronchiectasis 10.0 CYP11B2 NR3C2
44 panuveitis 10.0 AGTR1 CYP11B2 NR3C2
45 marfan lipodystrophy syndrome 10.0 AGTR1 CD36 MMP2
46 skin amelanotic melanoma 10.0 MMP1 MMP2
47 ischemia 10.0
48 cardiovascular organ benign neoplasm 9.9 CYP11B2 NR3C2
49 atrial fibrillation 9.9
50 hypoaldosteronism, congenital, due to cmo ii deficiency 9.9 AGT CYP11B2 NR3C2

Comorbidity relations with Hypertensive Heart Disease via Phenotypic Disease Network (PDN):


Acute Cystitis Heart Disease
Hypertension, Essential

Graphical network of the top 20 diseases related to Hypertensive Heart Disease:



Diseases related to Hypertensive Heart Disease

Symptoms & Phenotypes for Hypertensive Heart Disease

MGI Mouse Phenotypes related to Hypertensive Heart Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 CD36 CYP11B2 MMP2 MMP9 NR3C2 ACE
2 growth/size/body region MP:0005378 9.97 ACE AGT AGTR1 CD36 CTF1 CYP11B2
3 homeostasis/metabolism MP:0005376 9.96 ACE AGT AGTR1 CD36 CTF1 CYP11B2
4 adipose tissue MP:0005375 9.88 ACE AGT AGTR1 CD36 CTF1 CYP11B2
5 immune system MP:0005387 9.76 ACE AGT AGTR1 CD36 CYP11B2 MMP1
6 nervous system MP:0003631 9.56 MMP9 NR3C2 AGT AGTR1 CD36 CTF1
7 renal/urinary system MP:0005367 9.17 ACE AGT AGTR1 CD36 CYP11B2 MMP9

Drugs & Therapeutics for Hypertensive Heart Disease

Drugs for Hypertensive Heart Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 216)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Irbesartan Approved, Investigational Phase 4,Phase 2,Phase 3 138402-11-6 3749
2
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
3
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2 75847-73-3 5362032 40466924
4
Enalaprilat Approved Phase 4,Phase 3,Phase 2 76420-72-9 6917719
5
Eplerenone Approved Phase 4 107724-20-9 150310 443872
6
Spironolactone Approved Phase 4,Phase 3 1952-01-7, 52-01-7 5833
7
Amlodipine Approved Phase 4,Phase 3 88150-42-9 2162
8
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
9
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846
10
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
11
Carvedilol Approved, Investigational Phase 4,Phase 3 72956-09-3 2585
12
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
13
Allopurinol Approved Phase 4 315-30-0 2094
14
Nifedipine Approved Phase 4 21829-25-4 4485
15
Losartan Approved Phase 4,Phase 3,Phase 2 114798-26-4 3961
16
Indapamide Approved Phase 4 26807-65-8 3702
17
Furosemide Approved, Vet_approved Phase 4,Phase 3 54-31-9 3440
18
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
19
Metoprolol Approved, Investigational Phase 4,Phase 3 37350-58-6, 51384-51-1 4171
20
Chlorthalidone Approved Phase 4,Phase 3 77-36-1 2732
21
Adenosine Approved, Investigational Phase 4 58-61-7 60961
22
Regadenoson Approved Phase 4 313348-27-5 219024
23
Glyburide Approved Phase 4 10238-21-8 3488
24
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
25
Clopidogrel Approved, Nutraceutical Phase 4,Phase 2,Phase 3 120202-66-6, 113665-84-2 60606
26
Angiotensin II Investigational Phase 4,Phase 3,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
27 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 3,Phase 2
28 Angiotensin Receptor Antagonists Phase 4,Phase 3,Phase 2
29 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3,Phase 2
30 Angiotensinogen Phase 4,Phase 3,Phase 2
31 Antihypertensive Agents Phase 4,Phase 3,Phase 2
32 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
33
protease inhibitors Phase 4,Phase 3,Phase 2
34 Anticholesteremic Agents Phase 4,Phase 3
35 Antimetabolites Phase 4,Phase 3
36 Atorvastatin Calcium Phase 4 134523-03-8
37 Calcium, Dietary Phase 4,Phase 3,Phase 2
38 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 3
39 Hypolipidemic Agents Phase 4,Phase 3
40 Lipid Regulating Agents Phase 4,Phase 3
41 diuretics Phase 4,Phase 3,Phase 2
42 Diuretics, Potassium Sparing Phase 4,Phase 2,Phase 3
43 Hormone Antagonists Phase 4,Phase 3
44 Hormones Phase 4,Phase 3
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
46 Mineralocorticoid Receptor Antagonists Phase 4,Phase 3
47 Mineralocorticoids Phase 4,Phase 3
48 Natriuretic Agents Phase 4,Phase 2,Phase 3
49 Neurotransmitter Agents Phase 4,Phase 2,Phase 3
50 Platelet Aggregation Inhibitors Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 173)

id Name Status NCT ID Phase Drugs
1 Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan Unknown status NCT00517322 Phase 4 ramipril;irbesartan
2 Anti-Hypertensive Agent (ACEi) and Heart Function Improvement in Association With Rho Kinase Activity Changes in Human Unknown status NCT01069042 Phase 4 Enalapril
3 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients Unknown status NCT01503671 Phase 4 Atorvastatin
4 Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy Unknown status NCT01893788 Phase 4 Aliskiren;Eplerenone
5 Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study) Completed NCT00149227 Phase 4 Valsartan;Non-ARB
6 Effect of Amlodipine on Anti-platelet Drug Effect in Patients With Coronary Artery Disease Completed NCT01203696 Phase 4 Amlodipine;Amlodipine
7 To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure. Completed NCT00170924 Phase 4 Valsartan
8 The Optimization of Blood Pressure and Fluid Status Control With Eight-Polar Bioelectrical Impedance Analysis Completed NCT00852514 Phase 4
9 Impacts of Aldosterone Blockade on Myocardial Remodeling in Hypertensive Patients With Diastolic Failing Heart Completed NCT01944384 Phase 4 aldactone
10 Comparison of Effects of Telmisartan and Valsartan on Neointima Volume in Diabetes Completed NCT00599885 Phase 4 telmisartan;valsartan
11 The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease Completed NCT00673075 Phase 4 Nebivolol;Carvedilol
12 Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease Completed NCT01147705 Phase 4 Allopurinol;Placebo
13 I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy Completed NCT00362037 Phase 4 Irbesartan (Aprovel)
14 Nifedipine vs Telmisartan on Prevention of Atrial Fibrillation (AF) Recurrence in Hypertensive Patients With AF Completed NCT01435161 Phase 4 Nifedipine,;Telmisartan
15 Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients Completed NCT01284114 Phase 4 Aliskiren
16 Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy Completed NCT01425411 Phase 4 valsartan
17 ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling Completed NCT01176032 Phase 4 Aliskiren;Losartan;Amlodipine;Hydrochlorothiazide (HCTZ)
18 Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart Completed NCT01961323 Phase 4 Nebivolol
19 Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure. Completed NCT00409942 Phase 4 Torasemide Prolonged Release;Furosemide
20 Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J) Completed NCT00294567 Phase 4 Calcium channel blockers (amlodipine, azelnidipine)
21 Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults Completed NCT00753012 Phase 4 Lisdexamfetamine
22 Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation Completed NCT00307463 Phase 4
23 Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance Completed NCT00129233 Phase 4 Valsartan;Amlodipine
24 Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes Mellitus Completed NCT00982358 Phase 4 Valsartan
25 Reduction of Left Ventricular Hypertrophy After Eplerenone Therapy Completed NCT03186742 Phase 4 Eplerenone 50 mg Tab
26 Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF Recruiting NCT02589977 Phase 4 regadenoson
27 Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH Recruiting NCT03180593 Phase 4 Valsartan 80 mg
28 Open-Labeled PK-PD Studies of Metoprolol ER Recruiting NCT02417246 Phase 4 Toprol XL;Wockhardt metoprolol;Activas metoprolol
29 Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects Recruiting NCT03089333 Phase 4 Dapagliflozin 10mg;Glibenclamide 5Mg Tablet
30 Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD Active, not recruiting NCT02502981 Phase 4 Spironolactone;Chlortalidone
31 Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD Not yet recruiting NCT03279861 Phase 4 Entresto;Valsartan
32 Effect of Intensive Blood Pressure Control on Progression of Coronary Atherosclerosis: Randomized Evaluation by Intravascular Ultrasound Terminated NCT01230216 Phase 4 control systolic blood pressure less than 120 mmHg;control systolic blood pressure less than 140 mmHg
33 High-Dose Quinapril Versus Low-Dose Quinapril Plus Amlodipine in the Treatment of High-Risk Hypertensive Patients Terminated NCT00313547 Phase 4 Quinapril 40 mg;Quinapril 10 mg and amlodipine 5 mg
34 Effect of Eplerenone in Elderly Hypertensive Early Stage Chronic Kidney Disease (CKD) Patients Withdrawn NCT01302236 Phase 4 Eplerenone
35 A Comparison of the Effect of Carvedilol and Metoprolol on Airways Tone in Patients With Heart Failure Withdrawn NCT00384566 Phase 4 Carvedilol;Metoprolol
36 A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia. Withdrawn NCT02400775 Phase 4 Azilsartan
37 Treatment of Refractory Angina Pectoris by Shock Wave Therapy Unknown status NCT00776568 Phase 3 Anti-hypertensive drugs
38 Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension Unknown status NCT00644475 Phase 3 Imidapril;Candesartan
39 Novel Treatment for Coronary Artery Disease Unknown status NCT01228214 Phase 2, Phase 3 Placebo;amiloride
40 Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease Completed NCT00865501 Phase 3 spironolactone;placebo
41 Irbesartan and Atenolol in Hypertensive Heart Disease Completed NCT00389168 Phase 2, Phase 3 Irbesartan;Atenolol
42 Studies of Left Ventricular Dysfunction (SOLVD) Completed NCT00000516 Phase 3 enalapril
43 Multicenter Study of Iloprost Inhaled in Pulmonary Hypertension After Repair of Congenital Heart Diseases (CHD) Completed NCT01598441 Phase 3 iloprost nebuliser solution;distilled water
44 Randomized Trial of Dietary Intervention Therapy in Obese Hypertensives (DITOH) Completed NCT00000515 Phase 3
45 Study of Inhaled Iloprost in Pediatric Pulmonary Hypertension (PH) After Surgery Completed NCT01310751 Phase 2, Phase 3 iloprost nebuliser solusion;distilled water
46 Potassium and Sodium to Control Blood Pressure in Hypertensives Completed NCT00000509 Phase 3
47 Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan Completed NCT00417222 Phase 3 olmesartan medoxomil
48 Dietary Intervention Study for Hypertension (DISH) Completed NCT00000497 Phase 3
49 Control of Hypertension by Non-Pharmacologic Means Completed NCT00000498 Phase 3 antihypertensive agents
50 Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients. Completed NCT00775840 Phase 3 Candesartan;Placebo

Search NIH Clinical Center for Hypertensive Heart Disease

Genetic Tests for Hypertensive Heart Disease

Anatomical Context for Hypertensive Heart Disease

MalaCards organs/tissues related to Hypertensive Heart Disease:

39
Heart, Kidney, Endothelial, Bone, Monocytes, Testes, Tongue

Publications for Hypertensive Heart Disease

Articles related to Hypertensive Heart Disease:

(show top 50) (show all 379)
id Title Authors Year
1
Comparison of Pulmonary Venous and Left Atrial Remodeling in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy Versus With Hypertensive Heart Disease. ( 28214001 )
2017
2
Relaxation and the Role of Calcium in Isolated Contracting Myocardium From Patients With Hypertensive Heart Disease and Heart Failure With Preserved Ejection Fraction. ( 28784688 )
2017
3
Regression of Established Cardiac Fibrosis in Hypertensive Heart Disease. ( 28379281 )
2017
4
Fragmented QRS: A marker of hypertensive heart disease? ( 28721702 )
2017
5
The emerging role of Cardiovascular Magnetic Resonance in the evaluation of hypertensive heart disease. ( 28535761 )
2017
6
A Novel Index of Remodeling in Hypertensive Heart Disease. ( 28847912 )
2017
7
Cardiac magnetic resonance imaging provides a new insight in hypertensive heart disease. ( 28139099 )
2017
8
Cardiac magnetic resonance imaging provides new insight into hypertensive heart disease-a reply. ( 28139052 )
2017
9
Hypertrophic cardiomyopathy and left ventricular hypertrophy in hypertensive heart disease with mildly reduced or preserved ejection fraction: insight from altered mechanics and native T1 mapping. ( 28552325 )
2017
10
Autoantibody profiling on a plasmonic nano-gold chip for the early detection of hypertensive heart disease. ( 28630342 )
2017
11
High fat diet aggravates atrial and ventricular remodeling of hypertensive heart disease in aging rats. ( 28888352 )
2017
12
MiR-19b and miR-16 cooperatively signaling target the regulator ADRA1A in Hypertensive heart disease. ( 28531963 )
2017
13
Carotid artery intima-media thickness and hypertensive heart disease: a short review. ( 28373912 )
2017
14
Fibrosis quantification in Hypertensive Heart Disease with LVH and Non-LVH: Findings from T1 mapping and Contrast-free Cardiac Diffusion-weighted imaging. ( 28373647 )
2017
15
The Relationship Between Left Ventricular Wall Thickness, Myocardial Shortening, and Ejection Fraction in Hypertensive Heart Disease: Insights From Cardiac Magnetic Resonance Imaging. ( 27316563 )
2016
16
Effect of Renal Sympathetic Denervation on Specific MicroRNAs as an Indicator of Reverse Remodeling Processes in Hypertensive Heart Disease. ( 26916982 )
2016
17
The septal bulge-an early echocardiographic sign in hypertensive heart disease. ( 26850524 )
2016
18
SY 05-2 PROGRESSION OF HYPERTENSIVE HEART DISEASE: NEW THERAPEUTIC APPROACH. ( 27753836 )
2016
19
Aircraft, road and railway traffic noise as risk factors for heart failure and hypertensive heart disease-A case-control study based on secondary data. ( 27667192 )
2016
20
Myocardial triglyceride content in patients with left ventricular hypertrophy: comparison between hypertensive heart disease and hypertrophic cardiomyopathy. ( 27142065 )
2016
21
Cardiac Fibrosis in Aortic Stenosis and Hypertensive Heart Disease Assessed by Magnetic Resonance T1 Mapping. ( 28238233 )
2016
22
Prognostic Implications of LV Strain RiskA ScoreA inA Asymptomatic Patients WithA Hypertensive Heart Disease. ( 27344417 )
2016
23
SY 05-2 PROGRESSION OF HYPERTENSIVE HEART DISEASE: NEW THERAPEUTIC APPROACH. ( 27642889 )
2016
24
JS ISH-ESH-2 UPDATE ON THE DETECTION AND FOLLOW-UP OF EARLY HYPERTENSIVE HEART DISEASE. ( 27754006 )
2016
25
Hypertensive heart disease versus hypertrophic cardiomyopathy: multi-parametric cardiovascular magnetic resonance discriminators when end-diastolic wall thickness a8Y 15 mm. ( 27368925 )
2016
26
Shape analysis of hypertrophic and hypertensive heart disease using MRI-based 3D surface models of left ventricular geometry. ( 26766206 )
2016
27
Case 2/2016 - 76-Year-Old Male with Hypertensive Heart Disease, Renal Tumor and Shock. ( 27305288 )
2016
28
Recurrent Syncope: An Unusual Complication of Hypertensive Heart Disease. ( 27448490 )
2016
29
Electrocardiography for Assessment of Hypertensive Heart Disease: A New Role for an Old Tool. ( 27160048 )
2016
30
Screening and Treatment for Subclinical Hypertensive Heart Disease in Emergency Department Patients With Uncontrolled Blood Pressure: A Cost Effectiveness Analysis. ( 27797437 )
2016
31
Obesity and hypertensive heart disease: focus on body composition and sex differences. ( 27956942 )
2016
32
JS ISH-ESH-2 UPDATE ON THE DETECTION AND FOLLOW-UP OF EARLY HYPERTENSIVE HEART DISEASE. ( 27642917 )
2016
33
The interplay between renin-angiotensin system activation, abnormal myocardial deformation and neurohumoral activation in hypertensive heart disease: a speckle tracking echocardiography study. ( 27787699 )
2016
34
Comprehensive characterisation of hypertensive heart disease left ventricular phenotypes. ( 27260191 )
2016
35
Fragmented QRS complexes are a marker of myocardial fibrosis in hypertensive heart disease. ( 27774963 )
2016
36
Factors associated to hypertensive heart disease development: a prospective cohort study in Bayamo, Cuba. ( 27571318 )
2016
37
Increased extracellular volume and altered mechanics are associated with LVH in hypertensive heart disease, not hypertension alone. ( 25577446 )
2015
38
Galectin-3 and Hypertensive Heart Disease. ( 26693838 )
2015
39
T1 Mapping in Discrimination of Hypertrophic Phenotypes: Hypertensive Heart Disease and Hypertrophic Cardiomyopathy: Findings From the International T1 Multicenter Cardiovascular Magnetic Resonance Study. ( 26659373 )
2015
40
Myostatin and insulin-like growth factor-1 in hypertensive heart disease: a prospective study in human heart donors. ( 25915890 )
2015
41
Serum Amyloid P-Component Prevents Cardiac Remodeling in Hypertensive Heart Disease. ( 26577946 )
2015
42
Myocardial dysfunction in patients with aortic stenosis and hypertensive heart disease assessed by MR tissue phase mapping. ( 26687082 )
2015
43
Association of impaired left ventricular twisting-untwisting with vascular dysfunction, neurohumoral activation and impaired exercise capacity in hypertensive heart disease. ( 26443037 )
2015
44
Safety of digoxin use in patients with hypertensive heart disease and atrial fibrillation. ( 26039531 )
2015
45
Hypertensive heart disease in paced-hearts. ( 26522996 )
2015
46
The importance of left ventricular geometry in hypertensive heart disease. ( 25915870 )
2015
47
Macrophages dictate the progression and manifestation of hypertensive heart disease. ( 26539962 )
2015
48
Hypertensive heart disease and bronchodilators: Potential left ventricular outflow obstruction. ( 26093159 )
2015
49
Long-term physiological T3 supplementation in hypertensive heart disease in rats. ( 26254335 )
2015
50
CMR imaging of extracellular volume and myocardial strain in hypertensive heart disease. ( 25677890 )
2015

Variations for Hypertensive Heart Disease

Expression for Hypertensive Heart Disease

Search GEO for disease gene expression data for Hypertensive Heart Disease.

Pathways for Hypertensive Heart Disease

GO Terms for Hypertensive Heart Disease

Cellular components related to Hypertensive Heart Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 ACE AGT CTF1 MMP1 MMP2 MMP9
2 extracellular space GO:0005615 9.17 ACE AGT CD36 CTF1 MMP2 MMP9

Biological processes related to Hypertensive Heart Disease according to GeneCards Suite gene sharing:

(show all 29)
id Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.84 AGT CD36 CTF1 NPPB
2 positive regulation of cytosolic calcium ion concentration GO:0007204 9.8 AGT AGTR1 CD36
3 kidney development GO:0001822 9.75 ACE AGT AGTR1
4 extracellular matrix disassembly GO:0022617 9.72 MMP1 MMP2 MMP9
5 regulation of blood pressure GO:0008217 9.7 ACE AGT NPPB
6 collagen catabolic process GO:0030574 9.69 MMP1 MMP2 MMP9
7 positive regulation of protein tyrosine kinase activity GO:0061098 9.64 ACE AGT
8 blood vessel remodeling GO:0001974 9.64 ACE AGT
9 endodermal cell differentiation GO:0035987 9.63 MMP2 MMP9
10 positive regulation of epidermal growth factor receptor signaling pathway GO:0045742 9.63 AGT MMP9
11 regulation of blood vessel size GO:0050880 9.62 AGT NPPB
12 nitric oxide mediated signal transduction GO:0007263 9.61 AGT CD36
13 positive regulation of cellular protein metabolic process GO:0032270 9.61 AGT AGTR1
14 low-density lipoprotein particle remodeling GO:0034374 9.59 AGT AGTR1
15 positive regulation of renal sodium excretion GO:0035815 9.58 AGT NPPB
16 angiotensin maturation GO:0002003 9.57 ACE AGT
17 positive regulation of cholesterol esterification GO:0010873 9.56 AGT AGTR1
18 positive regulation of reactive oxygen species metabolic process GO:2000379 9.54 AGT AGTR1 CD36
19 regulation of vasoconstriction GO:0019229 9.5 ACE AGT AGTR1
20 positive regulation of NAD(P)H oxidase activity GO:0033864 9.49 AGT AGTR1
21 renin-angiotensin regulation of aldosterone production GO:0002018 9.48 AGT AGTR1
22 regulation of renal sodium excretion GO:0035813 9.46 AGT AGTR1
23 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.43 AGT AGTR1
24 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.43 AGT MMP2 MMP9
25 regulation of renal output by angiotensin GO:0002019 9.4 ACE AGT
26 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.33 AGT AGTR1 CD36
27 cell growth involved in cardiac muscle cell development GO:0061049 9.3 AGT
28 regulation of blood vessel diameter GO:0097746 9.13 ACE AGTR1 NPPB
29 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 8.8 ACE AGT AGTR1

Molecular functions related to Hypertensive Heart Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.72 ACE MMP1 MMP2 MMP9 NR3C2
2 peptidase activity GO:0008233 9.67 ACE MMP1 MMP2 MMP9
3 metalloendopeptidase activity GO:0004222 9.43 MMP1 MMP2 MMP9
4 endopeptidase activity GO:0004175 9.33 ACE MMP1 MMP9
5 metallopeptidase activity GO:0008237 9.26 ACE MMP1 MMP2 MMP9
6 bradykinin receptor binding GO:0031711 8.62 ACE AGTR1

Sources for Hypertensive Heart Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....